Generally, low cardiovascular risk is typically defined as the absence of cardiovascular disease and a Flemingham 10-year risk of cardiovascular events less than 20% ( Conclusion In conclusion, our meta-analysis showed that first-line use of SGLT2i and GLP-1RAs in T2DM patients at low cardiovascular disease risk significantly reduced HbA1c, body weight, and FPG levels in T2DM patients compared with placebo
Many actionable tools are reviewed and discussed related to fasting, ketogenic and plant-based diets, probiotics, fermented foods, fish oils, artificial sweeteners, specific supplements that promote dopamine and serotonin, and some remarkable behavioral (and belief) effects
GLP-1 Patches: Do They Work For Weight Loss
Why Consistency Matters One of the biggest misconceptions surrounding peptides is the idea that a single injection should create dramatic healing on its own
Mikulska P, et al
These are not small differences